THE University of South Australia (UniSA) and global immunology company argenx have signed a strategic partnership to develop a pioneering molecule for autoimmune diseases, marking the first such collaboration for argenx in Australia.
Argenx's Immunology Innovation Program fosters close collaboration with leading disease biologists worldwide to identify novel therapeutic targets for rare and underserved immunological disorders and move them towards commercialisation.
Through this initiative, argenx and UniSA are working together to advance a monoclonal antibody candidate, currently in preclinical development, with the goal of addressing diseases that present significant unmet medical needs.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Oct 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Oct 25
